These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38691665)

  • 1. Edaravone Oral Suspension: A Neuroprotective Agent to Treat Amyotrophic Lateral Sclerosis.
    Singh P; Belliveau P; Towle J; Neculau AE; Dima L
    Am J Ther; 2024 May-Jun 01; 31(3):e258-e267. PubMed ID: 38691665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment.
    Genge A; Pattee GL; Sobue G; Aoki M; Yoshino H; Couratier P; Lunetta C; Petri S; Selness D; Bidani S; Hirai M; Sakata T; Salah A; Apple S; Wamil A; Kalin A; Jackson CE
    Muscle Nerve; 2023 Feb; 67(2):124-129. PubMed ID: 36504406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis.
    Shimizu H; Nishimura Y; Shiide Y; Akimoto M; Yashiro M; Ueda M; Hirai M; Yoshino H; Mizutani T; Kanai K; Kano O; Kimura H; Sekino H; Ito K
    Clin Ther; 2023 Dec; 45(12):1251-1258. PubMed ID: 37953075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
    Bhandari R; Kuhad A; Kuhad A
    Drugs Today (Barc); 2018 Jun; 54(6):349-360. PubMed ID: 29998226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Edaravone May Prevent Ferroptosis in ALS.
    Spasić S; Nikolić-Kokić A; Miletić S; Oreščanin-Dušić Z; Spasić MB; Blagojević D; Stević Z
    Curr Drug Targets; 2020; 21(8):776-780. PubMed ID: 32077821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics.
    Dash RP; Babu RJ; Srinivas NR
    Clin Pharmacokinet; 2018 Nov; 57(11):1385-1398. PubMed ID: 29682695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Edaravone for the treatment of amyotrophic lateral sclerosis.
    Yoshino H
    Expert Rev Neurother; 2019 Mar; 19(3):185-193. PubMed ID: 30810406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral Edaravone - Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis.
    Pattee GL; Genge A; Couratier P; Lunetta C; Sobue G; Aoki M; Yoshino H; Jackson CE; Wymer J; Salah A; Nelson S
    Expert Rev Neurother; 2023; 23(10):859-866. PubMed ID: 37646130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Oral Form for ALS Drug.
    Aschenbrenner DS
    Am J Nurs; 2022 Sep; 122(9):24-25. PubMed ID: 36005791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects.
    Shimizu H; Nishimura Y; Shiide Y; Yoshida K; Hirai M; Matsuda M; Nakamaru Y; Kato Y; Kondo K
    Clin Pharmacol Drug Dev; 2021 Oct; 10(10):1188-1197. PubMed ID: 33955162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
    Jaiswal MK
    Med Res Rev; 2019 Mar; 39(2):733-748. PubMed ID: 30101496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis-a systematic review and meta-analysis.
    Luo L; Song Z; Li X; Huiwang ; Zeng Y; Qinwang ; Meiqi ; He J
    Neurol Sci; 2019 Feb; 40(2):235-241. PubMed ID: 30483992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Logistics and safety of edaravone treatment for amyotrophic lateral sclerosis: experience in Argentina.
    Quarracino C; Bendersky M; Rey R; Rodríguez GE
    Acta Neurol Belg; 2021 Dec; 121(6):1519-1523. PubMed ID: 32436077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion.
    Brooks BR; Jorgenson JA; Newhouse BJ; Shefner JM; Agnese W
    Am J Manag Care; 2018 Apr; 24(9 Suppl):S175-S186. PubMed ID: 29693363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CNM-Au8: an experimental agent for the treatment of amyotrophic lateral sclerosis (ALS).
    Bireley JD; Morren JA
    Expert Opin Investig Drugs; 2023; 32(8):677-683. PubMed ID: 37642362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System.
    Vu M; Tortorice K; Zacher J; Dong D; Hur K; Zhang R; Good CB; Glassman PA; Cunningham FE
    JAMA Netw Open; 2020 Oct; 3(10):e2014645. PubMed ID: 33017028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Adamantane-Containing Edaravone Conjugates as Potential Neuroprotective Agents for ALS Treatments.
    Lapshina MA; Shevtsova EF; Grigoriev VV; Aksinenko AY; Ustyugov AA; Steinberg DA; Maleev GV; Dubrovskaya ES; Goreva TV; Epishina TA; Zamoyski VL; Makhaeva GF; Fisenko VP; Veselov IM; Vinogradova DV; Bachurin SO
    Molecules; 2023 Nov; 28(22):. PubMed ID: 38005288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients.
    Park JM; Kim SY; Park D; Park JS
    Neurol Sci; 2020 Jan; 41(1):119-123. PubMed ID: 31471712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolated pulmonary recovery in a veteran with late stage bulbar ALS following edaravone treatment and cessation.
    Verma S; Lim J; Buscemi-Kimmins T; Brose SW
    J Spinal Cord Med; 2022 Jul; 45(4):638-642. PubMed ID: 34982644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease-modifying treatment of amyotrophic lateral sclerosis.
    Schultz J
    Am J Manag Care; 2018 Aug; 24(15 Suppl):S327-S335. PubMed ID: 30207671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.